What Supranil Treats: Main Uses and Benefits

Supranil is centrally focused on providing relief for the burden of Obsessive-Compulsive Disorder (OCD), and is considered relevant in contexts marked by increased discomfort or tension. The use targets symptoms that cause marked distress and significantly interfere with daily stability.

Core Therapeutic Scope

Supranil is commonly used to help with conditions presenting with disruptive symptom manifestations, including managing the intensity of recurring obsessions and the compelling need to perform compulsions. It is generally applied in addressing the core symptoms of Major Depressive Disorder (MDD), the intense surges of fear characteristic of Panic Disorder, and specialized neurological symptoms like cataplexy associated with narcolepsy. This usage contributes to improved comfort during periods of heightened symptoms.

“This medication is applied across therapeutic domains where additional symptomatic support is needed for chronic, persistent symptoms.”

Quick Fact: Relief for Compulsive Behaviors

Quick Fact: Relief for Compulsive Behaviors Supranil may assist with managing symptoms related to heightened physiological activity, which contributes to easing the overall symptom load. This supports general well-being with symptom fluctuations.

Who Can and Cannot Use Supranil (Clomipramine)

Official regulatory documentation strictly defines the eligible population for Supranil, focusing on age restrictions, concurrent health conditions, and drug-use history.

---

Populations for Whom Use Is Contraindicated

Use of Supranil is absolutely prohibited (contraindicated) for individuals with a known hypersensitivity to clomipramine or other tricyclic antidepressants. It must not be used concurrently with, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI). Other contraindications include being in the acute recovery period following a myocardial infarction (MI), having severe liver disease, or having certain cardiac arrhythmias or heart block.

---

Age and Physiological Restrictions

Adults are the primary eligible population. Use in children under 10 years of age is not established for any indication, and use in adolescents is not recommended for indications other than Obsessive-Compulsive Disorder (OCD). Older adults require special caution due to increased sensitivity and must be closely monitored. During pregnancy and lactation, use is not recommended unless the potential benefit justifies the risk, as the drug is excreted in human milk.

Interactions with other medicines and products

Official regulatory documents categorize the known interactions for Supranil primarily based on pharmacokinetic and pharmacodynamic effects.

Interaction Scope and Constraints

Interacting Agents
Potent CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin), Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole), P-glycoprotein (P-gp) Substrates (e.g., Digoxin, Quinidine), Acid-Reducing Agents (e.g., PPIs, H2-receptor antagonists), and Medicinal products that prolong the QT interval (e.g., certain antiarrhythmics).

Supranil is subject to pharmacokinetic changes via the Cytochrome P450 3A4 (CYP3A4) enzyme system and is noted as a P-gp substrate. Co-administration with strong CYP3A4 inhibitors results in a significant increase in Supranil's systemic exposure ( AUC and C max), which is officially classified as an 'Avoid Combination' restriction in the absence of dose modifications.

Pharmacodynamic interactions include the additive potential for QTc interval prolongation when combined with other agents known to affect cardiac repolarization, necessitating clinical monitoring. For co-administration with acid-reducing agents, a timing-based rule is required, mandating a minimum separation of at least two hours to prevent reduced absorption and loss of efficacy. The official labeling also restricts the co-ingestion of grapefruit juice due to its effect as a CYP3A4 inhibitor, resulting in increased drug levels.

Mechanism of Action: Cathepsin K Inhibition

Supranil is a selective, oral small molecule inhibitor of Cathepsin K. Upon systemic absorption, the compound is distributed to osseous tissue and acts as a competitive antagonist, binding non-covalently to the active site of the Cathepsin K enzyme. Cathepsin K is a cysteine protease primarily responsible for the degradation of Type I collagen and other non-collagenous proteins within the bone matrix.

Downstream Physiological Effect

This specific binding event forms a stable drug-enzyme complex, leading directly to a marked reduction in the enzyme’s proteolytic activity within the osteoclast’s resorption lacuna. This molecular cascade consequentially reduces the localized rate of bone resorption. Supranil demonstrates a selectivity for Cathepsin K, which alters the kinetic balance of bone turnover at the tissue level.

How to Use Supranil: Official Administration Guidelines

The usage of Supranil (Clomipramine Hydrochloride) follows a structured, standardized protocol focusing on administration route, dose progression, and required timing. This information describes the procedural steps for its delivery.

---

Administration Scope

Instruction Entity	Clinical Guidelines
Route of administration	Primarily Oral (capsules/tablets) for long-term use. Intravenous (IV) Infusion and Intramuscular (IM) Injection are secondary routes for acute or initial treatment in certain clinical settings.
Dosing schedule	Treatment begins with a low initial dose (typically 25 mg daily) and is subject to gradual titration to a maintenance range, commonly between 100 mg and 150 mg per day. The maximum daily dose is 250 mg for adults.
Timing in relation to meals	Oral doses may be administered with meals during the initial titration phase to mitigate gastrointestinal discomfort.
Age-group administration rules	Older Adults require a lower starting dose and a lower maximum maintenance dose (e.g., 75 mg daily). Pediatric patients (10+ years) for certain uses have a maximum dose constraint of 200 mg per day or 3 mg/kg per day, whichever is smaller.

---

Resulting Procedural Structure

Official step sequence:

• Initiation: Start with the recommended low initial oral dose, given once daily or in divided doses.
• Titration & Timing: Gradually increase the dose over a period of weeks. The final daily amount is typically consolidated and taken once daily at bedtime during the maintenance phase.
• Discontinuation: Cessation of therapy requires a gradual dose reduction (tapering) over several weeks and must not be stopped abruptly.

Research Evidence / Overview of studies for Supranil

---

Research Evidence for Obsessive-Compulsive Disorder (OCD)

Research examining Clomipramine Hydrochloride in conditions characterized by fluctuating or episodic manifestations, such as Obsessive-Compulsive Disorder (OCD), has been explored in multiple clinical trials. Researchers primarily utilized Randomized, Placebo-Controlled Trials (RCTs), systematic reviews, and meta-analyses. Findings describe patterns observed in the studies related to how measurements of symptom scale scores changed in the observed populations compared to those who received a placebo.

Research provides insight into short-term changes, as the most consistently characterized outcomes come from studies with shorter follow-up durations. While studies describe group patterns, long-term effects are not fully established. There is limited information for long-term outcomes regarding rates of sustained remission, and findings were mixed in some direct comparative assessments against other drug classes.

---

Research Evidence for Cataplexy Associated with Narcolepsy

Clomipramine Hydrochloride was studied for its application in cataplexy, a condition associated with narcolepsy that causes sudden loss of muscle control. The evidence base for this use was evaluated in clinical trials and smaller observational studies that are cited by specific national regulatory bodies. These studies were conducted during periods of increased symptom activity, and research examined outcomes describing episodic or acute changes.

Studies monitored the frequency and intensity of cataplexy episodes. The evidence suggests that while this use is supported by some regulatory contexts, systematic, large-scale research evidence is noted in the literature as being less extensive than for its use in OCD. Follow-up durations were limited, and available studies provide limited detail on the durability of the reported effects.

---

Evidence Gaps and Research Uncertainty

The research provides context, but evidence highlights what is known—and what is still uncertain. Findings were mixed in some studies comparing this agent to newer treatment classes, contributing to uncertainty in the broader evidence landscape.

Key limitations include that the follow-up durations were limited across many trials, meaning long-term effects are not fully established. While evidence is extensive for its core use in OCD, comparative evidence is lacking in certain contexts, and data for older adults remain insufficient. This means research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Common questions about Supranil (FAQ)

Q: How long does Supranil typically stay in your system after stopping it?

A: According to official product information, the active ingredient in Supranil (clomipramine) has a half-life, which is the time it takes for half the drug to leave the body, of approximately 21 hours. Its active form, N-desmethylclomipramine, also stays in the body for a similar period. This means the substance can take a few days to be mostly eliminated from the system.

Q: Can taking Supranil affect my sleep patterns?

A: Yes, official regulatory documents list difficulties with sleep as a possible adverse reaction. Specifically, the official prescribing information mentions both difficulty falling asleep and staying asleep (insomnia) as potential side effects associated with this medication.

Q: Can Supranil be used by people who are sensitive to certain dyes or fillers?

A: The official product labeling provides a list of inactive ingredients used in the manufacturing of Supranil capsules. These ingredients may include specific colorants such as D&C Red No. 33, D&C Yellow No. 10, FD&C Blue No. 1, and titanium dioxide. Individuals who have sensitivities to inactive ingredients may wish to discuss this information with a healthcare professional.

Q: Are there any known drug-herb interactions with Supranil?

A: Yes, regulatory documents highlight potential interactions with certain herbal products. For instance, co-administration with St. John’s Wort may increase the risk of a serious condition called Serotonin Syndrome. Healthcare providers rely on complete patient information, including all herbs and supplements being taken, to review for potential interactions.

Q: Does the effectiveness of Supranil decrease over time?

A: Research evidence for Supranil primarily focuses on short-term outcomes, and long-term effects are less fully established. Research indicates that long-term studies are less fully established, and some findings have suggested variability in sustained long-term remission.

Q: Is Supranil available in different formulations (e.g., tablet, capsule, liquid)?

A: The medication is available in several forms, primarily for oral use. The most common forms are capsules, which are available in different strengths according to the official product information.

Q: Can diet influence how well Supranil works?

A: While the medication can generally be taken with or without food, official regulatory guidance specifically restricts the co-ingestion of grapefruit juice. Grapefruit juice can affect how the body processes the medication, potentially leading to increased drug levels in the bloodstream.

Q: How long does the primary benefit of a single dose of Supranil last?

A: Supranil is typically prescribed to be taken once daily at bedtime for maintenance therapy. This once-daily dosing at bedtime is the standard for maintenance therapy, consistent with the drug's half-life.

Q: Is it safe to drive or operate machinery while taking Supranil?

A: Official patient counseling information advises that Supranil may affect a person's alertness, coordination, and judgment. Because this medication may affect alertness or coordination, official guidance recommends caution regarding driving or operating machinery until the patient is aware of the drug's individual effects.

Q: Why do some people experience headaches when starting Supranil?

A: Headache is listed in the official prescribing information as a potential side effect that some individuals may experience when beginning treatment with this medication.

Q: Can Supranil cause changes in mood or emotional state?

A: Yes, official warnings mention that Supranil can cause changes in mood or emotional state. These changes include the risk of increased agitation, irritability, and other abnormal behaviors, particularly in adolescents and young adults during the initial stages of treatment.

Q: Are there any long-term monitoring tests required while on Supranil?

A: Regulatory documents recommend ongoing monitoring during treatment. This includes regular checks of liver enzyme levels and close observation for clinical worsening or the emergence of concerning changes in behavior or mood.

Q: What are the signs that Supranil might not be working for me?

A: Official research measures treatment outcomes using symptom scale scores. A lack of measured improvement or the development of unmanageable adverse reactions are factors considered when evaluating the success of the treatment.

Q: How soon after starting Supranil will my doctor review my progress?

A: Official patient counseling guidelines state that a doctor should check a patient's progress at regular visits. Official guidance also notes the importance of vigilance by caregivers and family members for changes in mood or symptoms, particularly in the beginning of therapy.

Q: Is Supranil a habit-forming or addictive medication?

A: The medication is addressed in the drug abuse and dependence sections of the official labeling. Abrupt cessation of this medication is associated with the potential for withdrawal symptoms.

Q: Do I need to take Supranil with food or on an empty stomach?

A: According to the official prescribing information, Supranil for oral use may generally be administered either with food or on an empty stomach.

The official regulatory documents for the trade name Supranil do not contain specific storage and disposal requirements. In the absence of label-specific instructions, official government guidance from the U.S. Food and Drug Administration (FDA) is followed for proper disposal of unused medicines.

Official Disposal Methods

• Preferred Method: Use a drug take-back program or a pre-paid mail-back envelope when available, as this is the safest method to remove unused medicine from the home.
• Flushing (High-Risk Drugs): If a drug is on the official FDA Flush List because it poses a high risk of fatal harm from accidental ingestion, it must be immediately flushed down the toilet.
• Household Trash (Most Drugs): For medicines not on the flush list, remove the drug from its original container, mix it with an undesirable substance (such as dirt, cat litter, or used coffee grounds), and place the mixture in a sealed container (like a plastic bag or empty can) before throwing it in the household trash.

Handling Requirement: Always scratch out all personal information from the empty medicine packaging before discarding it to protect privacy.